Investigation of the Effect of Horizontal Platelet Rich Fibrin Placed in Tooth Extraction Sockets on Bone Formation
Launched by TOKAT GAZIOSMANPASA UNIVERSITY · May 30, 2025
Trial Information
Current as of November 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is checking whether placing a healing material made from the patient’s own blood, called horizontal platelet-rich fibrin (H-PRF), in the site of a tooth extraction helps bone healing and improves the chance of a successful dental implant later. It compares three groups: no material placed in the socket (control), a similar material made as leukocyte platelet-rich fibrin (L-PRF), and the H-PRF material. The study is being done at Tokat Gaziosmanpasa University in Turkey, and treatment is randomized so people don’t know which group they’re in.
If you might be eligible, you would be an adult aged 18–40 in generally good health (no pregnancy, not on blood thinners, and not having radiotherapy to the head/face), and you’d need to have a tooth extracted with plans to get an implant later. About 30 participants are planned. What to expect: you’ll have the tooth extracted under local anesthesia, and depending on your group you may receive H-PRF, L-PRF, or nothing in the socket. Your blood will be drawn to prepare the PRF materials, and you’ll take part in follow-up checks over about a week, with imaging after the extraction and again around 3 months (before your implant). Some details, like a small bone sample during the future implant surgery, may be collected for research. The study is currently enrolling by invitation and does not have results yet. It’s a single‑blind trial (you won’t know your group) and led by the university’s study team.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Volunteer ASA I individuals between the ages of 18-40
- • Individuals with indication for tooth extraction
- • Patients who want to have implants after tooth extraction
- Exclusion Criteria:
- • Those who are pregnant or lactating
- • Those receiving anticoagulant or antiplatelet drug therapy
- • Those who received radiotherapy to the head and face area
About Tokat Gaziosmanpasa University
Tokat Gaziosmanpasa University is a distinguished academic institution dedicated to advancing medical research and innovation through rigorous clinical trials. With a commitment to enhancing healthcare outcomes, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct comprehensive studies that address critical health challenges. By fostering collaboration among researchers, healthcare professionals, and industry partners, Tokat Gaziosmanpasa University aims to contribute valuable insights to the scientific community and improve patient care through evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokat, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported